Skip to main content

Novel Rx

      #EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients we

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 2 weeks ago
      #EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients were “Super-Responder” (>3yrs response) inc. 7% IS-free after one Rituximab cycle. Non-European, APS & shorter disease duration predicted super-response @RheumNow https://t.co/nPIYpGoynR
      Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many confounding parameters, such as disease duration, disease state, and disease activity come into play. A promising session explored comorbidities in Rheumatoid Arthritis, in particular cancer and cardiovascular events. Here are my takeaways.
      Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.
      Using Combination csDMARDs in PsA
      #EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 2 weeks ago
      #EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib were maintained through to Week 104. Those who switched from PBO at WK48 to UPA + ELSU also improved. No VTE or MACE. Is add-on ELSU really needed? @RheumNow https://t.co/x8NbAtsHh0
      #Vagal #nerve #stimulation
      Hand held device
      #BDMARD failure
      Plausible - improved pro inflammatory cytokines

      wears off

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      #Vagal #nerve #stimulation Hand held device #BDMARD failure Plausible - improved pro inflammatory cytokines wears off benefit if stopped Attenuates in ~half over yrs Open label uncontrolled @RheumNow @eular_org #EULAR2025 Session D2T-RA https://t.co/98K5gwasHv
      Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.
      Fascinating to see JAKi uptake in European JAK-pot centres
      - tofa was already on the decline pre-ORAL Surveillance
      - JAK

      David Liew drdavidliew

      4 months 2 weeks ago
      Fascinating to see JAKi uptake in European JAK-pot centres - tofa was already on the decline pre-ORAL Surveillance - JAKi use (driven by upadacitinib) continues to grow, although maybe it’s slowed Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821
      New dual-action RA drug?
      OP0193: CPL’116 targets both JAK & ROCK.
      In 12-wk RCT, highest dose improved DAS28-CRP,

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      New dual-action RA drug? OP0193: CPL’116 targets both JAK & ROCK. In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs. Is this a future option for RA-ILD or patients with comorbid CVD risk? #EULAR2025 @RheumNow
      PHOENYCS GO🏃: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) a

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      PHOENYCS GO🏃: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) at wk48 vs PBO+SOC. DZP showed earlier & more sustained disease control, advancing T2T in SLE. @RheumNow #EULAR2025 #OP0201 https://t.co/zuxBELxTDd
      Ph 2 RCT CPL'116 dual inhibition JAK/ROCK
      106 MTX IR pts
      wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs.

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      Ph 2 RCT CPL'116 dual inhibition JAK/ROCK 106 MTX IR pts wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO 75% >= AEs, SAE 2: 1 MI, 1 bladder cancer Authors suggest absence of lipids/LFTs disruption compared to other JAKs Ph3 is awaited!! #OP0193 #EULAR2025 https://t.co/TnnM410LfM
      #MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for f

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      #MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for flare vs PBO: 0.12-0.16 across sex/race. Similar results for all subgroups in achieving flare-free, treatment-free complete remission. @RheumNow #EULAR2025 #OP0189
      There is still hope for vagal nerve stimulation in RA!
      RCT RESET-RA 240+pts multibioIR
      Implantable cervical device
      Meet

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      There is still hope for vagal nerve stimulation in RA! RCT RESET-RA 240+pts multibioIR Implantable cervical device Meets Primary endpoint ACR 20 wk12 Subgroup 1 prior bioDMARD ACR 20 wk12 46% vs 19% sham EULAR Good response 61% vs 42% sham Wk 12 SAE rate 1.7% #OP0190 #EULAR2025 https://t.co/DCON01XXgd
      2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in remission at wk104. Low relapse rate, no loss of asthma control or decline of lung function. No new safety signals. @RheumNow #EULAR2025 #OP0166 https://t.co/kXh2q2ilJF
      ×